

Interface and Formulary Update - Issue 33 – December 2024 and January 2025

Key messages from December 2024 and January 2025 TAG meetings (ratified by Medicines Optimisation Programme Board)

Commissioning Review GTN patches for Achilles Tendinopathy	<ul style="list-style-type: none"> • BLACK – not commissioned. Not for prescribing in primary or secondary care
Commissioning Review Tirzepatide for weight management	<ul style="list-style-type: none"> • BLUE - NWICB are committed to fund positive NICE TA treatments. Awaiting clarification of place in pathway and commissioning arrangements. Further guidance will be issued when available. For all other treatments, formulary application and discussion will be required pending publication of NHSE guidance and confirmation of local implementation arrangements. • Local guidance to be updated • Ensure there are no requests for weight management treatment under guise of diabetes care
Commissioning Review HidraWear dressings	<ul style="list-style-type: none"> • BLACK – not commissioned. Not for prescribing in primary or secondary care • Patients should be advised to purchase
Commissioning Review Hybrid Closed Loop Systems for managing blood glucose levels in Type 1 Diabetes	<ul style="list-style-type: none"> • Amended from BLUE to RED / HOSPITAL - Prescribing to remain with the hospital or specialist service. No prescribing in primary care •
Formulary Application and Guideline Proton Pump Inhibitors (PPIs) for paediatric and neonatal patients >1 month old and Omeprazole suspension	<ul style="list-style-type: none"> • GREEN - Drugs that can be initiated in primary care. • Omeprazole suspension will be limited to patients under 10kg who have an NG or PEG tube and for infants under 4 kg without an NG or PEG tube. • Guidance document supported by TAG

Shared Care Updates

Use of Testosterone Therapy for Boys in Infancy and Adolescence

Amendments include:

- Available preparations updated and topicals added
- Dose information updated

Traffic Light Additions / Updates (to be read in conjunction with [TAG Agreement document](#))

Hospital	TA1009 – October 2024 - Latanoprost–netarsudil (Roclanda®) for previously treated primary open-angle glaucoma or ocular hypertension
	TA1011 – October 2024 - Belzutifan (Welireg®) for treating tumours associated with von Hippel-Lindau disease
	TA1013 – October 2024 - Quizartinib (Vanflyta®) for induction, consolidation and maintenance treatment of newly diagnosed FLT3-ITD-positive acute myeloid leukaemia
	TA1010 – October 2024 - Danicopan (Voydeya®) with ravulizumab or eculizumab for treating paroxysmal nocturnal haemoglobinuria
	TA1012 – November 2024 - Avapritinib (Ayvakyt®) for treating advanced systemic mastocytosis
	TA1014 – November 2024 - Alectinib (Alecensa®) for adjuvant treatment of ALK-positive non-small-cell lung cancer
	TA1015 – November 2024 - Teclistamab (Tecvayli®) for treating relapsed and refractory multiple myeloma after 3 or more treatments
	TA1016 – November 2024 - Elafibranor (Iqirvo®) for previously treated primary biliary cholangitis
	TA1017 – November 2024 - Pembrolizumab (Keytruda®) with chemotherapy before surgery (neoadjuvant) then alone after surgery (adjuvant) for treating resectable non-small-cell lung cancer
	TA1018 – November 2024 - Fedratinib (Inrebic®) for treating disease-related splenomegaly or symptoms in myelofibrosis
	TA1019 – November 2024 - Crovalimab (Piasky®) for treating paroxysmal nocturnal haemoglobinuria in people 12 years and over
	TA1020 – November 2024 - Eplontersen (Wainzua®) for treating hereditary transthyretin-related amyloidosis
	TA1022 – December 2024 - Bevacizumab gamma (Lytenava®) for treating wet age-related macular degeneration
	TA1021 – December 2024 - Crizotinib (Xalkori®) for treating ROS1-positive advanced non-small-cell lung cancer (Replaces TA529)
TA1023 – December 2024 - Elranatamab (Elrexio®) for treating relapsed and refractory multiple myeloma after 3 or more treatments	
TA1025 – December 2024 - Ublituximab (Briumvi®) for treating relapsing multiple sclerosis	
BLUE	TA1026 – December 2024 - Tirzepatide (Mounjaro®) for managing overweight and obesity
BLACK	TA1024 – December 2024 - Toripalimab with chemotherapy for untreated advanced oesophageal squamous cell cancer (terminated appraisal)

Formulary and Guidance Updates

Formulary Amendments

- **Sucalfate Enemas - RED / HOSPITAL - Prescribing to remain with the hospital or specialist service. No prescribing in primary care** added to [Netformulary](#) - should be supplied by the specialist gastro teams. They should not be prescribed in primary care
- **Abidec drops for preterm infants** - change classification from **non-formulary** to '**OTC / on specialist advice**' for pre-term infants in accordance with the EOE ODN guidelines - [EOE_Vitamin_Iron_guideline_July-2024.pdf](#). After stopping 0.6ml dose (maximum age of 1 year, actual age and not corrected) this should switch to OTC (healthy start or alternative age-appropriate liquid supplement)
- **Tranexamic Acid Mouthwash - RED / HOSPITAL - Prescribing to remain with the hospital or specialist service. No prescribing in primary care.**
- **Acetylcysteine eye drops (Ilube)** - Changed from **GREEN** to **ADVICE - GP prescribable after consultant/specialist recommendation**. Not listed on primary care dry eye pathway and wouldn't be initiated in primary care

Wording updates as part of Chapter 4 Netformulary review to provide quality assurance to existing local arrangements:

- **Bupropion Hydrochloride (Zyban®)** – Old **GREEN** classification changes to **ADVICE - GP prescribable after consultant/specialist recommendation where the specialist is a smoking cessation adviser (level 2 or 3)**.
- **Varenicline (Champix®)** – Maintain **ADVICE** category that was agreed at TAG in July 2007 and add **"GP prescribable after consultant/specialist recommendation where the specialist is a smoking cessation adviser (level 2 or 3)"** To remove mention of 'Champix' as this brand has been discontinued. Varenicline only available as generic.
- **Nicotine (various)** – **GREEN - Eligible patients should still be referred to smoking cessation service. GPs are able to prescribe for patients who are not eligible (including those who have recently been discharged from hospital and children over 12). Patients can also purchase NRT products from their Community Pharmacist.**
- **Acamprosate – Red Specialist Only. Prescribing of treatments for alcohol misuse, including acamprosate and disulfiram (and also nalmefene) are the responsibility of the specialist since local alcohol misuse services are not commissioned from GPs practices.**
- **Nalmefene – Red Specialist Only. Prescribing of treatments for alcohol misuse, including acamprosate and disulfiram (and also nalmefene) are the responsibility of the specialist since local alcohol misuse services are not commissioned from GPs practices.**

Guidance Updates

- [Care Home](#) Best Practice Guidance
 - Self Care
 - Homely Remedies
 - PRN Protocols
 - Bisphosphonates
 - Methotrexate
 - Eye Drops and Ointment
- [Repeat Prescribing](#)
 - Electronic Repeat Dispensing Guidance for Norfolk & Waveney GP Practices
 - Cancelling an eRD Prescription
 - Adding a SNOMED Clinical Term
 - How to recognise suitable eRD patients and how to find these patients using SystmOne clinical searches
 - Setting up an eRD
 - Patient consent
 - Training for practices
- Key Message - [7-Day Prescriptions](#)
- Key Message - [Provision of Medicines Compliance Aids \(MCAs\)](#)
- How to add hospital prescribed medication to the patient medication record on [SystmOne](#) / [Emis](#)
- [Procedure for Initiating](#) Covert Administration
- Covert Administration – [Executive Summary](#)
- [Guidance](#) on the use of covert administration of medication in care homes
- [Home Oxygen Pathway](#) – High flow oxygen for the acute management of cluster headaches
- [Tracheostomy and Laryngectomy](#) Fair Usage Policy
- [Stoma](#) Fair Usage Policy

Useful Information

Next TAG meeting	Wednesday 5th February 2025
Deadline for agenda submissions	Tuesday 28th January 2025

Netformulary	Norfolk and Waveney Formulary (norfolkandwaveneyformulary.nhs.uk)
Knowledge NoW – Medicines Optimisation Home Page	Prescribing, Pharmacy and Medicines Optimisation - Knowledge NoW (nwknowledgenow.nhs.uk)
TAG Guidance	Therapeutic Advisory Group (TAG) and Commissioning - Knowledge NoW (nwknowledgenow.nhs.uk)
Shared Care Agreements	Shared Care Agreements - Knowledge NoW (nwknowledgenow.nhs.uk)
Pathways and Prescribing Guidance	Pathways and Prescribing Guidance - Knowledge NoW (nwknowledgenow.nhs.uk)
Practice Support	Practice Support - Knowledge NoW (nwknowledgenow.nhs.uk)
Useful Links	Useful Links - Knowledge NoW (nwknowledgenow.nhs.uk)

- Please remember to check both [KNoW](#) and [Netformulary](#) for regular formulary updates
- If you have any interface or formulary queries, please send to the inbox - nwicb.medsqueries@nhs.net